NASHVILLE, Tenn., April 12, 2024--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Key Insights Institutions' substantial holdings in Revance Therapeutics implies that they have significant influence...
NASHVILLE, Tenn., March 27, 2024--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)